📅 PUBMED DAILY TRIAGE — 2026-06-20

Window: 2026-06-19T09:00:00Z → 2026-06-20T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~200 candidates | Kept: 20 High priority: 2 | Standard: 18 | Low/archive: not counted Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

T1: Hematologic Malignancies

TR-2026-06-20-001 · [PMID 42320760] · Chromoanagenesis in Myelodysplastic Syndromes Is Associated With Highly Complex Karyotype, TP53 Disruption and Dismal Prognosis · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE

Mod Pathol — MD Anderson (Medeiros, Garcia-Manero, Tang) — n=332 MDS patients: OGM reveals chromoanagenesis (CAG) in 15.9% of MDS, nearly all with multi-hit TP53 and complex karyotype; CAG-defined MDS has median OS 9.9 months — worse than any other very-high-risk IPSS-M category. OGM enables routine detection and may immediately refine risk stratification beyond current frameworks.

T9: Rare Diseases

TR-2026-06-20-002 · [PMID 42318512] · Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency · 8/10 · 🟠 NOVEL_TREATMENT

Brain Commun — n=218 (104 treated, 114 untreated): First FDA/EMA-approved therapy for TK2 deficiency (doxecitine/doxribtimine) approximately doubles restricted mean survival (29.2 vs 14.4 years over 30 years in early-onset). Motor milestone recovery and reduced ventilatory/feeding support documented. Acceptable safety. Primary efficacy dataset behind regulatory approval for this uniformly fatal ultra-rare mitochondrial myopathy.

🟢⚪ STANDARD (5-7) — Top by Topic

T1: Hematologic Malignancies

• TR-2026-06-20-003 [42321829] · APLL hemorrhage risk + EASIX risk stratification, multicenter Chinese cohort · 7/10 · J Transl Med
• TR-2026-06-20-004 [42321403] · CAR-T vs alloSCT in R/R LBCL stratified by IPI; CART superior only in low/intermediate IPI (EBMT n=515) · 7/10 · Bone Marrow Transplant
• TR-2026-06-20-005 [42315131] · Tirabrutinib RCT protocol (JCOG2314 ReSTART) vs WBRT in refractory CNS lymphoma, 49 institutions · 7/10 · Jpn J Clin Oncol (deferred from 2026-06-19)
• TR-2026-06-20-013 [42321916] · CHIP-AML22 pediatric AML complex RCT protocol (GO + quizartinib, NOPHO-DB-SHIP consortium) · 6/10 · Trials

T2: CBC/ML in Hematology

• TR-2026-06-20-012 [42321393] · ML predictive hematological biomarkers for radiation exposure — mouse models only · 5/10 · Commun Med (T2 zero-HIGH streak: Day 2)

T3: Early Cancer Detection

• TR-2026-06-20-006 [42321804] · Serum FAP+ exosome assay for LUAD early diagnosis; AUC 0.932, superior to CEA/NSE/CYFRA21-1 · 7/10 · J Nanobiotechnology 🔴 EARLY_CANCER_DETECTION
• TR-2026-06-20-014 [42321936] · Microbial cfDNA for rapid pathogen ID in clinical diagnostics (proof of concept) · 6/10 · Genome Med

T4: AI/ML Clinical Diagnostics

• TR-2026-06-20-010 [42321427] · Clinical LLM centered on EHR for diagnostic support, multi-center validation · 6/10 · NPJ Digital Med
• TR-2026-06-20-011 [42321574] · MRI nnU-Net model validation for automated neck LN segmentation in HNSCC · 6/10 · Neuroradiology 🟢 NEAR_TERM_IMPLEMENTABLE

T5: Precision Oncology

• TR-2026-06-20-007 [42320753] · NTRK fusion detection ultrarapid cartridge-based PCR validation · 6/10 · J Mol Diagn 🟢 NEAR_TERM_IMPLEMENTABLE
• TR-2026-06-20-016 [42321415] · T-DXd clinical responses in HER2+ molecularly defined ependymoma (n=2, first clinical evidence) · 6/10 · NPJ Precis Oncol ⚪ PROMISING_PRELIMINARY

T6: Novel Therapeutics

• TR-2026-06-20-004 [42321403] (see T1 above, cross-listed)
• (T6 zero-HIGH streak: Day 3)

T7: Cardiovascular-Metabolic

• TR-2026-06-20-008 [42321502] · GLP-1 RA + muscle health meta-analysis of RCTs (n=821): lean mass ratio improved despite absolute loss · 6/10 · Int J Obes
• TR-2026-06-20-009 [42320483] · GZR18 long-acting GLP-1 analog phase 1b/2a RCT: HbA1c -1.81% vs placebo; safe · 6/10 · Cell Rep Med ⚪ PROMISING_PRELIMINARY
• TR-2026-06-20-015 [42321509] · Dulaglutide in RRMS RCT (n=28): metabolic improvement + functional trends; no NfL change · 6/10 · Neurol Ther ⚪ PROMISING_PRELIMINARY
• TR-2026-06-20-020 [42320716] · Semaglutide vs SGLT2i comparative real-world effectiveness in MASLD · 5/10 · Endocr Pract
• (T7 zero-HIGH streak: Day 3)

T8: Aging/Longevity

• TR-2026-06-20-019 [42317976] · Grip strength mediates frailty-depression link in older adults, multinational longitudinal · 5/10 · Front Public Health
• (T8 zero-HIGH streak: Day 3)

T9: Rare Diseases

• TR-2026-06-20-017 [42318138] · SENS-501 dual-AAV otoferlin gene therapy for DFNB9 congenital deafness: preclinical efficacy + NHP safety, phase 1/2 ongoing · 6/10 · Mol Ther Adv
• TR-2026-06-20-018 [42321174] · In vivo lentiviral gene therapy for ARC syndrome: rescued survival + liver function in mouse model (Nat Commun, UCL/GOSH) · 5/10 · Nat Commun

💡 UNSOLICITED FINDS

None — no out-of-watchlist items reached HIGH threshold today.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 6 (42320760, 42321829, 42320753, 42321804, 42321936, 42321574)
• Treatment Innovation: 8 (42318512, 42321403, 42315131, 42321916, 42321509, 42321415, 42320716, 42320483)
• Drug Development: 2 (42318138, 42321174)
• Genomics/Precision Medicine: (cross-listed)
• Public Health: 1 (42317976)
• Early Detection: 1 (42321804)

By evidence maturity:

• Validated: 6
• Exploratory: 14

By source type: peer_reviewed: 20 | preprint: 0

By watchlist topic (reviewed / kept / highest score):

Topics with zero 8+ articles today (streak):

• T2 CBC/ML: Day 2
• T3 Early cancer detection: Day 2
• T4 AI/ML diagnostics: Day 2
• T5 Precision oncology: Day 2
• T6 Novel therapeutics: Day 3
• T7 Cardiovascular-metabolic: Day 3
• T8 Aging/longevity: Day 3

Topics with HIGH finds today (streak reset):

• ✅ T1: RESET (streak was Day 2; PMID 42320760 scored 8/10)
• ✅ T9: RESET (PMID 42318512 scored 8/10)

🔧 RUN NOTES

• Deferred PMIDs resolved: All 20 deferred PMIDs from 2026-06-19 (10 T9 + 10 Sentinel) were reviewed this run. Notable find: PMID 42315131 (tirabrutinib phase II/III protocol for refractory CNS lymphoma, 7/10 STANDARD).
• T2 alert: Only 1 result in 24h CRDT window; mouse model study (Communications Medicine). If T2 zero-human-signal streak continues Day 3, consider expanding to 48h window.
• T7 query refinement: Cochrane review of weight-reducing drugs in hypertension (PMID 42318855) appeared but lacked direct GLP-1/SGLT2 specificity. Batch noisy with reviews and animal studies. Recommend restricting T7 further to cardiovascular outcome RCTs.
• T9 major find: TK2 deficiency treatment (PMID 42318512) represents first FDA/EMA-approved therapy for a rare fatal mitochondrial disease — this is a strong pipeline signal.
• T1 major find: Chromoanagenesis in MDS (PMID 42320760) from MD Anderson refines MDS risk stratification beyond IPSS-M using OGM — near-term clinical implementable finding.
• Sentinel scan: 10 candidates reviewed; none met watchlist HIGH threshold.
• No window expansion triggered: All topics exceeded 5 relevant results; expansion to 48h not needed.
• Coverage completeness: All candidate PMIDs accounted for; run_status = SUCCESS.